Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Misses Expectations By $3.23 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Tuesday. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($3.23), FiscalAI reports. The company had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.74 million.

Armata Pharmaceuticals Stock Up 19.2%

Armata Pharmaceuticals stock opened at $10.24 on Wednesday. Armata Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $16.34. The company has a market capitalization of $375.09 million, a P/E ratio of -2.12 and a beta of 1.30. The stock’s 50 day moving average is $8.87 and its 200 day moving average is $6.58.

Institutional Investors Weigh In On Armata Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $284,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Armata Pharmaceuticals in the 4th quarter worth about $177,000. Renaissance Technologies LLC boosted its stake in Armata Pharmaceuticals by 65.9% in the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after purchasing an additional 27,200 shares in the last quarter. Millennium Management LLC purchased a new stake in Armata Pharmaceuticals during the 4th quarter valued at about $164,000. Finally, Jane Street Group LLC purchased a new stake in Armata Pharmaceuticals during the 4th quarter valued at about $108,000. 3.57% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ARMP has been the topic of a number of research reports. JonesTrading began coverage on shares of Armata Pharmaceuticals in a report on Monday, January 5th. They set a “buy” rating and a $15.00 target price on the stock. HC Wainwright increased their price target on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Armata Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.